Harrow, Inc. Deferred Tax Assets, Operating Loss Carryforwards, State and Local
Harrow, Inc. (HROW) had Deferred Tax Assets, Operating Loss Carryforwards, State and Local of $75.33 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal · last filed 2026-03-02
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $75.33M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $26.13M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $45.00M.
- 2021-12-31: Deferred Tax Assets, Operating Loss Carryforwards, State and Local $53.20M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards, State and Local | Deferred Tax Assets, Operating Loss Carryforwards, State and Local as first filed |
|---|---|---|
| 2025-12-31 | $75.33M 10-K · filed 2026-03-02 | |
| 2023-12-31 | $26.13M 10-K · filed 2024-03-19 | |
| 2022-12-31 | $45.00M 10-K · filed 2023-03-23 | |
| 2021-12-31 | $53.20M 10-K · filed 2022-03-10 | |
| 2020-12-31 | $60.91M 10-K · filed 2021-03-08 | |
| 2019-12-31 | $67.54M 10-K · filed 2020-03-13 | |
| 2018-12-31 | $64.63M 10-K · filed 2019-03-12 | |
| 2017-12-31 | $59.22M 10-K · filed 2018-03-08 | |
| 2015-12-31 | $52.33M 10-K · filed 2017-03-21 | $35.11M 10-K · filed 2016-03-23 |
| 2014-12-31 | $24.60M 10-K · filed 2015-03-12 | |
| 2013-12-31 | $15.78M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |